Abstract
Despite advances in medical treatment, the annual mortality associated with severe heart failure remains over 40%, and even in mild heart failure the associated mortality is 40% over 4 years. Once it has been demonstrated that the morbidity and mortality to heart failure can be adequately addressed by combinations of drug therapy, then it is logical to attempt to strip out redundant components of these therapeutic regimes. In the meantime, however, combination therapy is required to counter many of the pathophysiological facets of the heart failure syndrome, including fluid retention, neuroendocrine activation, progressive ventricular dysfunction, and sudden cardiac death. Diuretics and ACE inhibitors are well-established drug treatments. Digoxin appears to lessen the rate of progression of heart failure without altering survival. New evidence suggests that beta-blockers may be useful additions to the heart failure therapeutic armamentarium, although whether all beta-blockers are equally effective remains to be established.
Similar content being viewed by others
References
Cleland JGF, on behalf of the Task Force on Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741–751.
Narang R, Cleland JGF, Ball SG, et al. Mode of death in chronic heart failure: A request for more accurate classification. Eur Heart J 1996;17:1390–1403.
Jiang BY, Habib F, Oakley CM, Cleland JGF: Shortened duration of post-ischaemic hyperaemic blood flow in heart failure. Am J Cardiol 1995;77:300–302.
Puri S, Baker BL, Dutka DP, Oakley CM, Hughes JMB, Cleland JGF. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure: Its pathophysiological relevance and relationship to exercise performance. Circulation 1995;91:2769–2774.
Puri S, Baker BL, Oakley CM, Hughes JMB, Cleland JGF. Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure. Br Heart J 1994;72:140–144.
Cleland JGF. ACE inhibitors for the prevention and treatment of heart failure: Why are they “under-used”? J Hum Hyperten 1995;9:435–442.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.
Lechat P, Jaillon P, Fontaine ML, et al. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765–1773.
O'Connor CM, Belkin RN, Carson PE, et al. Effect of amlodipine on mode of death in severe chronic heart failure: The PRAISE trial. Circulation, in press.
Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441–1446.
Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease: Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 1992;86:12–21.
Anand IS, Veall N, Kalra GS, et al. Treatment of heart failure with diuretics: Body compartments, renal function and plasma hormones. Eur Heart J 1989;10:445–450.
Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299–305.
Cleland JGF, Dargie HJ, Robertson I, et al. Total body electrolyte composition in patients with heart failure: A comparison with normal subjects and patients with untreated hypertension. Br Heart J 1987;58:230–238.
Cleland JGF, Oakley CM. Vascular tone in heart failure: The neuroendocrine-therapeutic interface. Br Heart J 1991;66:264–267.
Cleland JGF, Dargie HJ. Heart failure, renal function, and angiotensin converting enzyme inhibitors. Kidney Int 1987;31:S220-S228.
Cleland JGF. The clinical course of heart failure and its modification by ACE inhibitors: Insights from recent clinical trials. Eur Heart J 1994;15:125–130.
Good JM, Peters M, Wilkins M, Jackson N, Oakley CM, Cleland JGF. Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol 1995;25:1273–1281.
Dossegger L, Aldor E, Baird MG, et al. Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure: A multicentre, double-blind, placebo-controlled trial. Eur Heart J 1993;14:18–23.
Good JM, Brady AJB, Noormohamed FH, Oakley CM, Cleland JGF. Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation 1994;90:220–224.
Good J, Frost G, Oakley CM, Cleland JGF. The renal effects of dopamine and dobutamine in stable chronic heart failure. Postgrad Med J 1992;68:S7-S11.
Good J, Sbarouni E, Frost G, Meek J, Oakley CM, Cleland JGF. Does digoxin facilitate the renal response to furosemide in heart failure? J Am Coll Cardi 1993;21(Suppl):467. (abstr)
Good J, Frost G, Oakley CM, Cleland JGF. Sodium restriction impairs a frusemide-induced diuresis in patients with heart failure. Euro Heart J 1992;13(Suppl):217. (abstr)
Ram CVS, Garret BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981;141:1015–1019.
Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981;63:645–651.
Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. Circulation 1993;87:VI78-VI87.
Cleland JGF, Cowburn PJ, McMurray JJV. Heart Failure: a systematic guide to clinical practice, in Cleland JGF (ed): London, Science Press, 1997.
Cohn JN, Ziesche SM, Loss LE, Anderson GF. Effect of felodipine on short-term exercise and neurohormones and long-term mortality in heart failure: Results of V-HeFT-III. Circulation 1995;92:I143. (abstr)
Dargie HJ, McMurray JJV. Diagnosis and management of heart failure. Br Med J 1994;308:321–328.
Cleland JGF, Gillen G, Dargie HJ. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J 1988;9:132–141.
Cleland JGF, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: A double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305–312.
Cleland JGF, Shah D, Krikler S, Dritsas A, Nihoyannopoulos P, Frost G, Oakley CM. Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J 1993;69:512–515.
Berglund H, Nyquist O, Beermann B, Jensen Urstad M, Theodorsson E. Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure. Br Heart J 1994;72:521–527.
Rouleau JL, Bichet D, Kortas C. Atrial natriuretic peptide in congestive heart failure: Postural changes and reset with chronic captopril therapy. Am Heart J 1988;115:1060–1067.
Cleland JGF, Cowburn PJ, Morgan K. Neuroendocrine activation after myocardial infarction: Causes and consequences. Br Heart J 1996, in press.
Riegger GAJ, Haeske W, Kraus C, et al. Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment. Am J Cardiol 1987;59:906–910.
Wieshammer S, Hetzel M, Hetzel J, Kochs M, Hombach V. Lack of effect of nitrates on exercise tolerance in patients with mild to moderate heart failure caused by coronary disease already treated with captopril. Br Heart J 1993;70:17–21.
Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724–1729.
Cleland JGF, Bristow M, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blockers in heart failure: Should they be used and how? Eur Heart J 1996, in press.
Anderson JL, Platia EV, hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction: A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation 1994;90:2843–2852.
Peters RW, Mitchell LB, Brooks MM, et al. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the cardiac arrhythmia suppression trial (CAST). J Am Coll Cardiol 1994;23:283–289.
Doval HC, Nul DR, Grancelli HI, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493–498.
Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Eng J Med 1995;333:77–82.
Cleland JGF, Dutka DP. Optimising heart failure pharmacotherapy: The ideal combination. Br Heart J 1994;72:S73-S79.
Cleland JGF, Puri S. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: Remodelling, resetting, or sudden death? Br Heart J 1994;72:S81-S86.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 1993;342:812–828.
Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Bri Heart J 1995;74:215–219.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cleland, J.G. Combination Drug Therapy in Chronic Heart Failure: Is Treatment Part of the Problem in Heart Failure?. Cardiovasc Drugs Ther 11 (Suppl 1), 297–303 (1997). https://doi.org/10.1023/A:1007700215917
Issue Date:
DOI: https://doi.org/10.1023/A:1007700215917